Biosynthesis of cell wall peptidoglycan (None)

Peptidoglycan biosynthesis is an essential cellular pathway in bacteria, responsible for creating the rigid layer that constitutes the bacterial cell wall. The pathway is a multistep process involving the cytoplasmic synthesis of precursor nucleotide-linked sugars, their attachment to a lipid carrier, and their polymerization into a mesh-like structure of alternating N-acetylglucosamine and N-acetylmuramic acid cross-linked by short peptides. Multiple dedicated enzymes (e.g., transferases, transpeptidases, transglycosylases, carboxypeptidases) catalyze each step. This pathway is a validated therapeutic target for antibacterial drugs, most notably β-lactam antibiotics like penicillin, which inhibit the transpeptidase responsible for cross-linking and thus weaken the bacterial cell wall, causing cell lysis. Human cells lack peptidoglycan, making this process highly selective for bacteria. Disruption of this pathway is lethal for bacteria and underpins the mechanism-of-action of many antibiotics; resistance arises primarily through changes in enzyme targets or acquisition of degrading enzymes. Note: As described, "biosynthesis of cell wall peptidoglycan" is a pathway, not a discrete molecular target. Individual enzymes (such as transpeptidase or specific PBPs) are considered canonical drug targets. For structured data extraction, you should select specific enzymes (e.g., "Peptidoglycan transpeptidase" or "Penicillin-binding protein 2") for maximal specificity.

Other names

Peptidoglycan biosynthesisCell wall peptidoglycan synthesisBacterial cell wall synthesis pathwayMurein biosynthesisIndividual enzymes: MurAMurBMurC-Etransglycosylasetranspeptidasepenicillin-binding proteins (PBPs)

Inhibition of transpeptidase (blocks cross-linking of peptidoglycan, e.g., β-lactams compete for D-Ala-D-Ala binding sites) - Inhibition of transglycosylase (blocks polymerization of glycan strands) - Inhibition of lipid carrier recycling (bacitracin) - Inhibition of precursor synthesis (fosfomycin blocks early precursor formation)